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a b s t r a c t
We show that minor capsid protein L2 is full length in clinical virion isolates and prepare furin-cleaved
pseudovirus (fcPsV) as a model of the infectious intermediate for multiple human papillomavirus (HPV)
types. These fcPsV do not require furin for in vitro infection, and are fully infectious in vivo. Both the
γ-secretase inhibitor XXI and carrageenan block fcPsV infection in vitro and in vivo implying that they act
after furin-cleavage of L2. Despite their enhanced exposure of L2 epitopes, vaccination with fcPsV
particles fails to induce L2 antibody, although L1-speciﬁc responses are similar to PsV with intact L2.
FcPsV can be applied in a simple, high-throughput neutralization assay that detects L2-speciﬁc
neutralizing antibodies with 410-fold enhanced sensitivity compared with the PsV-based assay.
The PsV and fcPsV-based assays exhibit similar sensitivity for type-speciﬁc antibodies elicited by L1
virus-like particles (VLP), but the latter improves detection of L1-speciﬁc cross-type neutralizing
antibodies.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Genital human papillomavirus (HPV) is one of the most
common sexually transmitted infections, and persistent infection
with 15 ‘high risk’ HPV genotypes (most often HPV16, HPV18,
HPV31, HPV45) frequently can cause high-grade intraepithelial
neoplasia. Left untreated, these high-grade lesions can progress to
invasive carcinoma of the cervix and other anogenital regions and
oropharynx. Indeed, HPV is the etiologic agent responsible for 5%
of all cancer deaths worldwide, including 99% of cervical cancers
(de Villiers et al., 2004; Parkin and Bray, 2006). As the two
prophylactic HPV vaccines, Gardasil and Cervarix, are licensed for
protection against only two oncogenic HPV types (HPV16 and
HPV18), the development of more broadly acting inhibitors and
second generation HPV vaccines has continued.
The study of papillomavirus has been technically difﬁcult because
completion of the PV life cycle requires squamous differentiation of
the infected keratinocyte that is not replicated by standard tissue
culture conditions. However, organotypic raft culture causes infected
keratinocytes to undergo squamous differentiation and thus gener-
ates infectious PV (Conway et al., 2009b; McLaughlin-Drubin et al.,
2004; Meyers et al., 1992). This method produces limited quantities of
virions containing the authentic viral genome for which there is no
simple per cell infectivity assay. An alternative approach is the
production of PV pseudovirion (PsV) by the co-transfection of the
293TT cell line with codon-modiﬁed L1 and L2 expression vectors and
a reporter plasmid genome (Buck et al., 2004). The cells are lysed 48 h
later, and incubated overnight at 37 1C (known as the maturation
step) before being puriﬁed by density gradient ultra-centrifugation.
These puriﬁed PsV can be readily used for surrogate infectious studies
both in vitro and in vivo because they deliver a reporter construct,
typically expressing luciferase or GFP, or alternatively the PV genomes
can be encapsidated in this system to produce quasivirions (QV) (Buck
et al., 2004; Culp et al., 2006; Pastrana et al., 2004; Pyeon et al., 2005;
Roberts et al., 2007).
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Residues 17-36 of minor capsid protein L2 are buried below the
capsid surface of HPV16 PsV, inaccessible to the neutralizing
monoclonal antibody RG1 (Gambhira et al., 2007), but become
accessible to RG1 as early as 4 h in the infectious process (Kines
et al., 2009). For exposure of the RG1 epitope, PV must ﬁrst
undergo a conformational change and adopt an intermediate
structure. This is triggered by binding of virions to heparan sulfate
proteoglycans (HSPG) on the basement membrane (that has been
revealed upon wounding the epithelium) and cleavage of the very
amino terminus of L2 by furin at a conserved site. This conforma-
tional change in the capsid is also modeled in vitro by the
association of PsV with extracellular matrix (ECM) produced by
certain cell lines, e.g. HaCaT and MCF7, although not 293TT cells to
which the PsV bind directly via HSPGs (Johnson et al., 2009; Kines
et al., 2009). Importantly this difference in mechanism of L2
exposure upon binding of PsV to 293TT cells has been linked to
poor sensitivity in L2-, but not L1 VLP-speciﬁc antibody-dependent
in vitro neutralization assays using this cell line (Day et al., 2008a,
2012a). Indeed, the discord between the low or undetectable
neutralization titers measured using this system despite robust
ELISA reactivity and protection upon passive transfer and PsV
challenge of mice with the same L2-vaccinated sera, suggest the
need for improved assays that use target cells other than 293TT to
better replicate the uncloaking of L2 observed during infection
in vivo.
Studies of the PsV production procedure show that HPV PsV
particles which do not undergo the maturation step are more
susceptible to neutralization by L2 antibodies, suggesting L2 is
initially exposed during the early events of packaging and co-
assembly with L1 capsomeres but is slowly “buried” in the capsid
structure as the virus matures into a more stabilized form (Buck
et al., 2005; Buck and Trus, 2012). In contrast, studies of organo-
typic raft culture-derived virions show more mature HPV virus
particles (i.e. virions from a 20-day old raft) harvested from
corniﬁed layer, are more susceptible to neutralization by L2-
speciﬁc antibodies compared to virions harvested from the supra-
basal layer of the tissue rafts cultured for 10 days (Conway et al.,
2011). These ﬁndings suggest differential exposure of L2 epitopes
on the capsid during virion morphogenesis and elevation from the
more reducing environment of the suprabasal layers to the upper
oxidizing corniﬁed layers in the differentiated tissue raft culture
(Conway et al., 2009b, 2011). Whereas some studies analyzing L2
in virions puriﬁed from warts suggest L2 is full-length, others
show L2 existing in a doublet by immunoblot (Doorbar and
Gallimore, 1987; Jin et al., 1989; Rose et al., 1990). While the latter
may reﬂect partial degradation during virion puriﬁcation, it
remains possible that a subset of wart-derived infectious virions
exhibit variable degrees of L2 exposure and furin-cleavage.
There are important implications if a subset of L2 is already
exposed and cleaved by furin even before transmission and
encountering the host. Firstly, partially pre-cleaved HPV can infect
both HSPG- or furin-deﬁcient cell lines (Day et al., 2008b; Kines
et al., 2009). This shows that changes in the conformation of the
capsid associated with L2 exposure and cleavage allows HPV to
become independent from cellular factors considered to be
required for infection. Importantly, carrageenan (a type of sulfated
polysaccharide extract from red algae which is used in sexual
lubricants) as well as inhibitors of γ-secretase (e.g. XXI) (Huang
et al., 2010; Karanam et al., 2010) were recently identiﬁed as
potent inhibitors of mucosal trophic HPV types infection (Buck
et al., 2006; Marais et al., 2011; Roberts et al., 2007). However, it is
currently unknown if their potency would be compromised if a
subset of, or the true infectious form of native virions are in the L2-
cleaved conformation. A second implication is that potential
differences in L2 cleavage within organotypic raft-derived virion
and PsV preparations may account for reported differences in
sensitivity to inhibitors and the impact of mutations in the RG1
epitope (Conway et al., 2009a; Cruz and Meyers, 2013).
Here we describe a method to generate milligram quantities of
highly (90% of L2) furin-cleaved pseudovirus (fcPsV), and exam-
ined their immunogenicity and the impact of carrageenan, and
furin and γ-secretase inhibitors upon infectivity of the furin-
cleaved intermediate. To conﬁrm if furin cleavage of L2 represents
an infectious intermediate, we examined the cleavage status of L2
in several wart-derived virions of divergent PV genotypes. Further,
we assessed if use of fcPsV for in vitro neutralization studies could
enhance the sensitivity for L2-speciﬁc neutralizing antibodies in a
high throughput format without compromising measurement of
L1 VLP-speciﬁc antibody.
Results
Generation of 293TTF, a clonal cell line that overexpresses
enzymatically active furin
L2 in HPV16 PsV could be cleaved if furin is added during the
maturation step of the standard HPV PsV protocol. However, the
extent of L2 cleavage in the virions was only approximately 35% in
these preparations (Day et al., 2008b). This prompted us to
develop an alternative approach to reproducibly produce fully
furin-cleaved PsV at high titer. To this end, a clonal 293TT cell line
that over-expresses furin, termed 293TTF, was generated from the
293TT cell line that is used for conventional PsV production
(Fig. 1).
Based upon functional analyses furin is present in 293TT cells
but the amounts were below the limit of detection in our Western
blot analysis (Fig. 1A, lane 1). This was consistent with the
literature on furin being highly regulated and not readily detected
via western blot methods (Bourne and Grainger, 2011; Thomas,
2002). However, Western blot analysis of 293TTF cells produced a
prominent band of 90–100 kDa, a size consistent with an unre-
solved doublet of the endogenous immature/pro-furin (96 kDa)
and mature furin (90 kDa) (Fig. 1A, lanes 3 and 4). Image analysis
by densitometry showed that the total amount of furin expressed
in 293TTF was at least 150-fold higher than in parental 293TT cells.
Another band was observed at 60 kDa which was reported in the
antibody material data sheet provided by the manufacturer as a
furin splice variant (Fig. 1A, lanes 1, 3, and 4). The level of secreted
furin released by 293TTF cells was also 200-fold higher compared
to 293TT cells (Fig. 1A, lane 5–7). Secreted furin has a lower
molecular weight (80 kDa) than cell-associated furin due to
cleavage of the latter's C-terminal transmembrane region.
Production and analysis of HPV furin-cleaved pseudovirus (fcPsV)
To assess if 293TTF can act as a producer cell line for furin-
cleaved pseudovirus (fcPsV), we performed the standard PsV
production protocol using either 293TT or 293TTF. Particles
puriﬁed from each preparation using Optiprep™ step gradients
were morphologically indistinguishable when stained with uranyl
acetate and viewed by transmission electron microscopy (Fig. 2A
and B).
To examine HPV16 fcPsV functionally, we tested whether fcPsV
produced from 293TTF could bypass the requirement for furin and
thus infect furin-deﬁcient cell lines such as FD11 (Chinese hamster
ovary-CHO cells with furin gene knocked out) (Gordon et al., 1995)
and LoVo (a human colon adenocarcinoma line) (Drewinko et al.,
1976). In FD11 cells, the infectivity of HPV16 fcPsV was 2 logs
higher than HPV16 PsV (Fig. 1B). Importantly, the infectivity of
HPV16 PsV was restored to levels similar to that of fcPsV in FD11-F
cells which are FD11 cells re-complemented for the wild type furin
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gene (Fig. 1C). A similar trend was observed with LoVo cells versus
LoVo supplemented with puriﬁed exogenous furin (data not
shown). HPV16 fcPsV and PsV infectivity in 293TT was also tested
with and without the presence of a furin inhibitor (20 μM). Both
HPV16 fcPsV and PsV were similarly infectious in 293TT cells
(Fig. 1D), whereas upon furin inhibition, HPV16 PsV infection
decreased dramatically by 2 logs. Interestingly, HPV16 fcPsV
infection was also affected whereby the infectivity decreased
almost 1 log10-fold compared to fcPsV infection without inhibitor.
This observation suggests that not all the virion particles in the
293TTF-made fraction were cleaved (Fig. 1E).
We next performed a time course infectivity experiment with
equal infectious units of GFP-encapsidated HPV16 PsV and fcPsV to
assess if furin-cleaved viruses delivered the marker gene more
rapidly since furin cleavage has been shown to be a rate-limiting
step for PV infectivity. The infectivity of HPV16 fcPsV is higher at
24 and 48 h, there was no signiﬁcant difference from the PsV at
72 h (Fig. 2C), consistent with the wave of PsV infection catching
up with the fcPsV. Similarly, the difference in infection of
luciferase-encapsidated HPV16 fcPsV and PsV after 72 h in vivo
when tested in a murine vaginal challenge model was not
signiﬁcant (Fig. 2D). These ﬁndings are consistent with fcPsV as
an infectious intermediate, and suggest that the altered puriﬁca-
tion protocol does not damage the structure or infectious potential
of fcPsV.
The furin inhibition results observed with HPV16 fcPsV in
Fig. 1E prompted us to check the extent of L2 cleavage in HPV16
fcPsV made with 293TTF using the standard HPV PsV protocol.
Densitometry results showed approximately half of the L2 of
HPV16 fcPsV was cleaved after 24 h maturation in these prepara-
tions from 293TTF cells, whereas cleavage of L2 in PsV prepared in
293TT was not observed (Supplementary Fig. 1A). The partial
cleavage of L2 supports the notion that not all virion particles
are cleaved hence explaining why there is a small but detectable
inhibition by furin seen in Fig. 1E. The partial cleavage of L2 despite
150-fold more furin in 293TTF (Fig. 1A), suggested suboptimal
conditions for furin proteolytic activity.
Studies of furin enzymology indicate that in vitro processing
and activation of transfected furin in cell lysates was optimal at pH
6.5–7 with a calcium concentration of 5 mM (Anderson et al.,
1997; Thomas, 2002; Vey et al., 1994). To optimize the maturation
conditions to obtain more fully cleaved L2 in fcPsV, we tested a
range of calcium chloride concentrations (2.5, 5 or 7.5 mM) with
24 h maturation (Fig. 2E). Our results indicated that addition of
CaCl2 beyond 5.0 mM calcium concentration was not beneﬁcial.
This was further substantiated in an infectivity test using 293T
cells in which the infecitivity of fcPsV virions matured with 5 mM
CaCl2 was almost the same as its no furin-inhibitor counterpart. In
contrast, the infecitivity results for HPV16 fcPsV matured without
5 mM CaCl2 in the presence or absence of furin inhibitor was
similar to the results seen in Fig. 1E (Supplementary Fig. 1B).
To further increase the proportion of L2 cleaved in the pseu-
dovirion preparations, we extended the maturation time to 48 h.
The L2 cleavage of HPV16, HPV18, HPV45 and HPV58 fcPsV
Fig. 1. 293TTF cell line overexpresses furin and facilitates production of furin-cleaved PsV. Expression of endogenous furin in parental 293TT cells (lane 1), 293TT transiently
transfected with furin gene (lane 2), 293TTF cells stably transfected with furin in the presence (lane 3) and absence (lane 4) of puromycin (2 μg/ml). Equivalent amounts of
conditioned media supernatant of parental 293TT (lane 5) or 293TTF in the presence (lane 6) and absence (lane 7) of puromycin (2 μg/ml) were used to assess furin secretion.
Image analyses and relative densitometry using ImageJ indicate that for 293TTF cells endogenous furin expression and secretion was at least 150-fold higher compared to
293TT control cells. Band seen at 60 kDa was a furin splice variant as indicated in the material data sheet of the antibody used (A). Equivalent amounts of HPV16 PsV (solid
squares) or HPV16 fcPsV (open squares) based on L1 content, were added onto pre-plated furin deﬁcient cells FD11 (B) or FD11F (FD11 cells re-complemented with furin
gene) (C), 293TT cells (D) and 293TT cells with 20 μM of furin inhibitor (E). All experiments were performed in triplicate
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generated using48 h maturation with 5 mM CaCl2 supplementa-
tion was at least 80%, whereas L2 remained intact in PsV prepared
using the standard protocol (Fig. 2F). Likewise, the fcPsV of all four
types were able to infect furin-deﬁcient cells, whereas conven-
tional PsV infected FD11 cells minimally (data not shown).
L2 is full length in natural papillomavirus virion isolates
Whereas some studies analyzing L2 in virions puriﬁed from
warts suggest that it is full-length, others show L2 existing in
multiple forms by Western blot analysis (Doorbar and Gallimore,
1987; Jin et al., 1989; Rose et al., 1990). These lower molecular
weight forms were explained as partial but unnatural degradation
that occurred during the virion puriﬁcation process. However, it is
possible that a subset of wart-derived infectious virions are
already furin-cleaved. Thus, to examine whether furin-cleaved
PV represents an infectious intermediate (i.e. it exists only
during the infectious process but in virions shed from the wart
into the environment), we compared the molecular weight of L2 in
regular PsV which are known to be uncleaved with L2 in PV
derived from human and animal clinical wart samples. Side-by-
side comparisons showed that PV L2 is uncleaved as only a single
band of the same size was observed (Fig. 3). In some preparations,
signiﬁcantly lower molecular weight L2 bands were also detected
near the 50–55 kDa region (Fig. 3C and D). However, based on our
puriﬁed fcPsV experiments which distinguishes furin-cleaved and
uncleaved L2, these lower L2 bands are not the furin-cleaved form
of L2, but likely rather L2 degraded during the preparation. Thus
the furin-cleaved form is an intermediate produced during the
infectious process rather than the fully mature infectious form.
Taken together, the results thus far indicate that fcPsV manufac-
tured in 293TTF cells are consistent with an intermediate con-
formation and potentially useful to study its biology.
Impact of carrageenan and heparin on fcPsV infectivity
It was previously suggested that both heparin and carrageenan
are highly inhibitory to HPV infection via blocking binding to and
Fig. 2. Furin-cleaved pseudovirus (fcPsV) exhibits 80–90% L2 cleavage without compromise of morphology or infectivity in vivo. Transmission electron microscopy of HPV16
PsV (180,000 ) (A) and fcPsV (135,000 ) (B), black bar indicates 100 nm. Infection time course of HPV16 PsV versus fcPsV encapsidating a GFP reporter was added to 293TT
cells (60,000 cells/well) (signiﬁcance was calculated using paired t-test: 24 h P¼0.0349, 48 h P¼0.0282, 72 h P¼0.0654) (C). In vivo vaginal challenge of mice for 72 h with
HPV16 PsV or fcPsV encapsidating a luciferase reporter (unpaired t-test, P¼0.0901), or PBS as negative control (D). Commassie gel showing L2 cleavage status of HPV16 PsV
using the standard PsV protocol or in 293TTF (fcPsV) matured in various calcium concentrations (0, 2.5, 5.0 and 7.5 mM) for 24 h (E) Western blot analysis of L2 cleavage on
HPV PsV genotypes 16, 18, 45, and 58 made either in 293TT with the standard HPV PsV protocol or in 293TTF with modiﬁed maturation timing of 48 h and 5 mM of calcium
chloride (F).
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causing conformational changes in the virion on the ECM (Buck
et al., 2006; Roberts et al., 2007). Since furin cleavage occurs after
PV adopts in its intermediate structure, the use of fcPsV particles
would allow us to assess whether these inhibitors act downstream
of these events. Indeed, we hypothesized that neither carrageenan
nor heparin would be inhibitory for HPV fcPsV infection as there is
no further need of fcPsV to undergo primary binding to the
extracellular matrix, as required to facilitate the conformational
change and L2 cleavage events that fcPsV have already undergone.
Unexpectedly, infection by fcPsV was still potently inhibited by
both heparin and carrageenan in 293TT cells with similar IC50
values to PsV which were used as a control (Fig. 4A and B). These
IC50 values were also consistent with published literature using
HPV PsV (Buck et al., 2006; Johnson et al., 2009) and the same
degree/pattern of inhibition of infection was observed in the
mouse vaginal challenge model using inhibitor concentrations
that were previously published (Fig. 4D) (Buck et al., 2006;
Johnson et al., 2009).
Both heparin and carrageenan could also inhibit fcPsV16
infection of PGSA-745 cells at high concentrations (Fig. 4C). Inter-
estingly, at lower concentrations of heparin or carrageenan, the
infectivity of fcPsV16 was enhanced slightly in heparin-deﬁcient
PGSA 745 cells (Fig. 4C) but not in 293TT cells (Fig. 4A and B). This
surprising phenomenon suggests that high quantities of either
heparin or carrageenan completely coat the virion and block all
receptor binding. Conversely, partial coating of fcPsV with heparin
or carrageenan may either enhance secondary L1 conformational
changes or bridge the interaction with HSPG-deﬁcient cells but not
cells with normal levels of HSPG. This observation is also consis-
tent with recent evidence (Cerqueira et al., 2013; Richards et al.,
2013; Surviladze et al., 2012) showing that soluble heparin and its
associated factors can form complexes with PV to initiate cell entry
and infection even in HSPG deﬁcient cells.
γ-Secretase is required for HPV infection after furin cleavage
We previously reported that PV infection requires γ-secretase
and that inhibitors of γ-secretase such as XXI potently block HPV
infection both in vitro and in vivo (Karanam et al., 2010). To
determine whether γ-secretase functions before or after furin-
cleavage of L2, we assessed the infectivity of HPV16 fcPsV and PsV
infection in the presence of XXI both in vitro and in vivo. XXI
inhibited fcPsV and PsV infection similarly, both in vitro and
in vivo, demonstrating that γ-secretase provides a critical function
in HPV infection after furin cleavage of L2 (Fig. 4E, F).
L2 exposure is enhanced in HPV16 fcPsV but it remains
immunologically subdominant
The majority of L2 is buried below the capsid surface of mature
virions, including residues 17–36 that are recognized by the cross-
neutralizing monoclonal antibody RG-1 (Gambhira et al., 2007).
However, conformational changes in the capsid and furin cleavage
of L2 during infection render the RG-1 epitope accessible once
HPV16 adopts its intermediate structure. To determine if fcPsV also
have this property, we performed immunoprecipitation of equal
amounts of puriﬁed HPV16 PsV or fcPsV with the RG-1. RG-1 was
able to pull down a signiﬁcant amount of HPV16 fcPsV but not PsV
(Fig. 5A) indicating that furin cleavage during fcPsV production
enhanced the exposure of L2 17-36 region upon the capsid surface,
consistent with an intermediate conformation. Importantly, since
fcPsV highly displays the L2 17-36 region (RG-1 epitope) on the
capsid surface, whereas mature PsV do not (Fig. 6E), we examined
whether L2 in fcPsV was still immunologically sub-dominant to L1.
Three groups of 10 mice were vaccinated three times each at 2
week intervals with PBS, HPV16 PsV or fcPsV particles respectively,
each formulated in alum and MPL adjuvant. Two additional groups
of 10 mice were also included in this study; one group was not
vaccinated, while the other group was vaccinated with 0.1 of a
human dose of CervarixTM. Subsequently, full length HPV16 L2
peptide or HPV16 PsV ELISA studies were performed on sera
obtained 2 weeks after the second vaccination or 2 weeks post
the ﬁnal vaccination. As a positive control for L2 ELISA responses,
sera from a previous study with 10 mice vaccinated with L2α(11–
88)x8 was used (Jagu et al., 2013b). These ELISA studies showed a
similarly robust HPV16 L1 VLP-speciﬁc antibody response in sera
Fig. 3. Absence of furin-cleaved L2 from papillomaviruses of natural isolates. Western blot of papillomavirus pseudovirions (PsV) and PV virions L2 extracted from clinical
isolates of warts of the same papillomavirus genotype; HPV26 (A), BPV-1 (B), HPV6 (C), HPV57 (D), MmuPV1 (E) and table showing classiﬁcation and clinical source of
respective papillomavirus.
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of mice vaccinated with PsV, fcPsV or CervarixTM after either two
or three doses. However, negligible L2-speciﬁc antibody levels
were detected L2-speciﬁc ELISA in either group, suggesting that L2
remains subdominant to L1 in fcPsV despite its surface display of
the 17–36 epitope (Fig. 5B).
Use of fcPsV to enhance detection of L2-speciﬁc neutralizing
antibodies
The ability to effectively detect L2-speciﬁc neutralizing anti-
bodies is critical to the development of several second generation
HPV vaccines. However considerable evidence suggests that the
standard in vitro HPV PsV neutralization assay (now termed as
293TT- or L1-assay) developed by Pastrana et al. (2004) is highly
effective for L1-speciﬁc responses, but lacks sensitivity for L2-
speciﬁc neutralizing antibodies. This lack of sensitivity was
attributed to the failure of the 293TT assay to replicate the
spacial-temporal separation between engagement with the pri-
mary and secondary receptors which limits the exposure of the
dominant L2 cross-neutralizing epitopes (e.g. L2 17-36) to the
antibodies. As the puriﬁed fcPsV already displays L2 17-36 on its
surface, and we hypothesized that its use in the 293TT assay
might therefore enhance sensitivity for the detection of L2-
speciﬁc neutralizing antibodies without compromise of L1-
speciﬁc measurements. Surprisingly, the substitution of HPV16
fcPsV into the framework of the existing 293TT assay failed to
Fig. 4. Heparin, Carrageenan and γ-secretase inhibitor (XXI) inhibit both HPV16 PsV and fcPsV. Inhibition assays were performed using equivalent amounts of HPV16 PsV
(solid circles) or fcPsV (open circles) based on L1 content with varying concentrations of heparin (A), carrageenan (B) in 293TT cells. The same assay was performed using
fcPsV16 infection of HSPG-deﬁcient PGSA-745 cell line in the presence of either heparin (open triangles) or carrageenan (closed triangles) (C). In vivo mouse (n¼5) vaginal
challenge of HPV16 fcPsV or PsV in the presence or absence of heparin or carrageenan (D). Inhibition assay using HPV16 fcPsV in the presence or absence of XXI (500 nM) in
FD11 cells (furin-deﬁcient CHO cells) (E). In vivomouse (n¼10) challenge with HPV16 fcPsV or PsV in the presence or absence of XXI. n indicates signiﬁcance (P value¼0.0089
for HPV16 PsV comparison, P value¼0.0101 for HPV16 fcPsV comparison).
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signiﬁcantly increase the sensitivity of the assay (data not
shown).
Studies have previously showed that HPV infection occurs
whereby virions can bind directly to 293TT cells and readily enter
the cell, thus avoiding the extended display of L2 by ECM-bound
virus and limiting opportunity for neutralization by L2 antibodies
in the milieu. Further, remaining uncleaved PsV in the fcPsV
preparations can still infect 293TT cells, and are possibly cleaved
by furin after their rapid uptake, rendering them resistant to L2-
speciﬁc neutralizing antibodies. To eliminate the latter issue,
293TT cells were substituted with a furin-deﬁcient line, FD11, as
the target cell. While this approach (termed ‘FD11 assay’) was
more sensitive in detecting L2-speciﬁc antibodies that neutralize
HPV16 (Table 1), the lack of the T-antigen in FD11 resulted in the
FD11 assays for several other HPV genotypes such as HPV18 PsV to
display poor reporter signals. This resulted in difﬁculty establish-
ing accurate 50% neutralization values. Furthermore, FD11 origi-
nates from hamster cells (CHO cells), and a human target cell
would potentially be more appropriate.
To improve infection sensitivity while maintaining a require-
ment for furin cleavage, we decided to create a human cell line for
detecting HPV neutralization via stably expressing the SV40
T-antigen (T-Ag) protein in LoVo cells, a human adenocarcinoma
cell line that is furin-deﬁcient and strongly expresses ECM. This
new cell line, called LoVoT, retained the susceptibility for infection
by fcPsV. Further, the LoVoT cells expresses the SV40 large T-
antigen that provides a higher reporter signal compared to FD11 or
the parental LoVo cells suggesting that a lower viral inoculum can
be utilized (Fig. 6A and B). Importantly, we assessed several L2-
speciﬁc sera and monoclonal antibodies using LoVoT as the target
cell line for HPV in vitro neutralization assays (termed ‘LoVoT
assay’) against furin-cleaved PsV of HPV types 16, 18, 31, 45, 58 and
6, in all cases, the detection sensitivity towards L2-based neutra-
lization titers for these HPV genotypes was higher by at least 10–
300 fold compared to titers detected by the 293TT assay (Table 2).
The LoVoT assay also demonstrated a similar sensitivity for HPV 16
(60,367, CI¼52,999–68,760 for 293TT versus 133,179, CI¼54,345–
326,373, for LoVoT) and HPV18 (512,462, CI¼459,833–571,115 for
293TT versus 419,401, CI¼284,189–615,995 for LoVoT) L1-speciﬁc
neutralizing antibodies induced by vaccination of mice with
CervarixTM, the licensed L1-based vaccine made from HPV16 and
HPV18 VLPs. Likewise, the LoVoT assay displayed similar sensitivity
towards HPV6 L1-speciﬁc neutralizing antibodies elicited by Gardasil
(92,623, CI¼ 71,929–119,271 for 293TT versus 73,113, CI¼49,166–
108,723 for LoVoT) (Table 2). Importantly, cross-neutralizing titers
were detected with the LoVoT assay against both HPV31 and HPV45 in
Fig. 6. Generation of LoVoT cell line. Stable expression of the SV40 T-antigen in LoVoT (lane 2) with parental LoVo cells (lane 1) and 293TT (lane 3) as controls (A). Validation
of LoVoT cell line demonstrating superior infectivity (luminescence signal) for the same input of fcPsV using virus dilution of 1:8000 (B).
Fig. 5. Vaccination with HPV16 fcPsV particles which have enhanced RG-1 epitope exposure does not elicit an enhanced L2 immune response. RG-1 Immunoprecipitation of
equivalent amount of HPV16 fcPsV and PsV (based on L1 content) and immunoblot with antibody to L1. The arrow indicates amount of L1 pulled-down (A). ELISA results for
mouse sera vaccinated with HPV16 PsV or fcPsV (plus alum-MPL adjuvant) using HPV16 PsV or full length HPV16 L2 peptide as antigens (B).
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serum frommice vaccinated with CervarixTM but the 293TT assay only
detected low titers from HPV31 (3331, CI¼1859–10,547 for 293TT
versus 4428, CI¼1459–7604 for LovoT) but not for HPV45 (o50 for
293TT versus 1712, CI¼917–3194 for LoVoT,). We have shown pre-
viously that vaccination with CervarixTM protects mice from vaginal
challenge with HPV31 and HPV45 PsV (Jagu et al., 2013b), and this is
also consistent with human data from clinical vaccine trials (Wheeler
et al., 2012). These results suggest that our new format neutralization
assay using fcPsV and the LoVoT line as target cells is a more sensitive
assay compared to the conventional 293TT neutralization assay for
detection of L2-speciﬁc and cross-neutralizing L1-speciﬁc antibodies
while retaining the standard assay's high sensitivity for type-speciﬁc
antibodies to L1 VLP, simplicity and throughput.
Discussion
L2 17-36 epitope exposure occurs as early as 4 h after addition
of virus to cultured cells, and the infectious process is slow such
that addition of antibody even 8 h later is still neutralizing (Kines
et al., 2009; Kreider et al., 1995), implying that HPV can exist in its
secondary furin-cleaved conformation at the cell surface for
several hours. This important insight may help explain why
prophylactic HPV vaccination is so effective, and it likely impacts
the measurement of L2-dependent neutralizing antibodies. In light
of this, our ability to purify 480–90% furin-cleaved HPV PsV
particles at milligram titers using our newly created cell line
293TTF provides the opportunity to study both basic and transla-
tional aspects of HPV in its furin-cleaved intermediate conforma-
tion in areas including structure, biology and immunology.
As expected, characteristics of furin-cleaved particles include
furin-independent infection (Fig. 1B and E). While some inhibition
was noted in the infectivity of HPV fcPsV16 in 293TT cells in the
presence of furin inhibitor (Fig. 1E), we showed that this inhibition
was due to the presence of uncleaved virions in the fcPsV
preparation. Indeed, optimizing the conditions during the virion
maturation period to enhance L2 cleavage increased the ratio of
fcPsV to PsV and promote higher furin-independent infectivity
(Fig. 2 and Supplementary Fig. 1). Given that fcPsV particles have
already bypassed the rate-limiting furin cleavage step, they should
also theoretically infect cells with a more rapid time course, and
we observed evidence for this at early time points of 24 and 48 h
post-infection. However the difference has narrowed by 72 h post
addition of virus to 293TT cells. Similarly, the in vivo infectivity of
PsV and fcPsV was not signiﬁcantly different at 72 h post-
challenge (Fig. 2C and D), suggesting sufﬁcient time for HPV PsV
to ‘catch up’ with the wave of fcPsV infection, as supported by our
time-based observations in Fig. 2C. Immuno-precipitation studies
also showed that the L2 epitope for RG-1 is more exposed upon
fcPsV than PsV (Fig. 5), demonstrating that their capsid conforma-
tions are distinct but the morphological changes are too subtle to
be resolved upon negative staining and transmission electron
microscopy (Fig. 2A and B). Taken together, these results further
demonstrate that fcPsV have distinct properties compared to pre-
infectious HPV virions (e.g. HPV PsV) and are consistent with HPV
in an infectious intermediate state that is characterized by the
furin-cleaved L2 and has RG-1 epitope exposed.
Studies on the mechanisms and neutralization of HPV infection
using PsV or virions derived from organotypic raft culture are
occasionally conﬂicting, which might potentially reﬂect differences
in their extent of furin L2 cleavage. Published studies of the state of PV
L2 in clinical samples showed L2 sometimes existing in a doublet
(Christensen et al., 1991; Doorbar and Gallimore, 1987; Jin et al., 1989;
Rippe and Meinke, 1989; Rose et al., 1990) which might be consistent
with furin cleavage rather than degradation. However, the in vivo
signiﬁcance of this doublet is controversial since in other studies, a
single band of L2 is observed (Carter et al., 1991; Holmgren et al.,
2005; Komly et al., 1986; Liu et al., 1997; Xi and Banks, 1991). This
raises the possibility that the fully matured infectious form
of papillomaviruses that is shed from the infected lesion is
furin-cleaved. Here, our study of L2 in PV virions isolated from several
human and animal papillomas did not detect any evidence to suggest
the presence of furin-cleaved L2 (Fig. 3). Although multiple sized
bands of L2 were seen in certain blots (Fig. 3C and D), the migration
pattern of the lower bands did not correlate with the expected 8–9
amino acid loss in which furin-cleaved L2 would display, as seen in
our furin cleavage experiments of puriﬁed PsV versus fcPsV in Fig. 2E
or F. Thus, the additional L2 bands observed are probably due to L2
degradation that occurs during the extraction and/or puriﬁcation
process. Importantly, our ﬁndings support the validity of the HPV
pseudovirus system and that the furin-cleaved form of PV virions is
an infectious intermediate rather than the fully mature
infectious form.
Carrageenan has shown promise clinically as a vaginal micro-
bicide for protection against sexual transmission of HPV (Marais
et al., 2011). While studies using puriﬁed HPV PsV show convin-
cingly that carrageenan is a potent inhibitor of infection by
uncleaved PsV of various HPV types both in vitro and in mice
(Buck et al., 2006; Roberts et al., 2007), it cannot be completely
ruled out that a small proportion of HPV virions upon natural
release is furin-cleaved (but not detected by our Western blot
analysis). Hence, it is important to assess if L2 cleavage by furin
renders this furin-cleaved form of HPV resistant to inhibition by
heparin or carrageenan. Given that fcPsV is able to infect HSPG-
deﬁcient cell lines, we expected HPV fcPsV to overcome heparin or
carrageenan inhibition. Indeed, our studies both in vitro and in vivo
using fcPsV demonstrated that the inhibitory potency of carragee-
nan or heparin was not compromised in HPV16 if L2 is cleaved
(Fig. 4A–D).
Interestingly, infection was enhanced at low concentrations of
carrageenan or heparin when infectivity was tested in the HSPG-
deﬁcient PGSA-745 cells (Fig. 4C). This likely reﬂects bridging
between L1 and an HSPG-binding cell surface protein to anchor
fcPsV to the surface of PGSA-745 cells and facilitate infection.
However once there is sufﬁcient carrageenan or heparin present to
coat the virus and the surface of the HSPG-deﬁcient PGSA-745
cells, infection is instead inhibited. Hence, this phenomenon
(Fig. 4C) which occurs in cells lacking HSPG is therefore likely
irrelevant in vivo.
Recently, Richards et al. identiﬁed two intermediate L1 con-
formational states prior to infectious entry. The ﬁrst state is
achieved after primary binding to HSPG speciﬁcally at Lys278
and Lys361 on L1 and is associated with L2 exposure and furin-
cleavage. The characteristics of the next state remain ill-deﬁned
but it is driven by interactions between HSPG and other L1
residues. Achieving the second intermediate state was important
for subsequent internalization and viral uncoating (Richards et al.,
2013). It is unclear which L1 conformational state is exhibited by
fcPsV but they do infect PGSA-745 cells, suggesting that further
HSPG-mediated secondary conformational changes in L1 are not
needed for subsequent internalization and uncoating in this
situation.
Our results using fcPsV indicate that carrageenan remains as a
promising topical HPV microbicide candidate and also further
elucidate carrageenan's mechanism of action. Previously, Buck
and colleagues suggested that the primary mechanism of inhibi-
tion is similar to heparin blocking the initial interaction between
HSPGs and the viral capsid. Further, it was shown that carrageenan
had a secondary inhibitory effect that was exerted after the virions
were cell-bound. This secondary inhibition was termed as ‘HSPG-
independent inhibition’ because it was reported using 50-fold
more HPV PsV pre-bound to PGSA-754 cells which do not have
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HSPG. However, the exact mechanism of this secondary inhibitory
mechanism was unclear, although two possible modes of actions
may be considered. Either the secondary inhibitory effect could
occur via preventing the interaction of HPV capsid with the
unknown secondary receptor necessary for the remainder of the
infectious process or carrageenan prevents the cell-bound HPV
pseudovirus from further conformational change to initiate furin
cleavage (Buck et al., 2006). Given that furin-cleaved HPV has most
likely already undergone the ﬁrst round of conformational change
which includes surface display of the amino-terminus of L2, our
results here suggest that the secondary inhibitory mechanism of
carrageenan is most likely the masking of virus surfaces involved
in binding to the secondary receptor and not the prevention of
initial conformational changes of the capsid that lead to L2
exposure and furin cleavage. This may also explain why carragee-
nan is a more potent inhibitor of HPV compared to heparin, as the
latter only inhibits the interaction with the primary receptor.
We recently discovered γ-secretase inhibitor XXI is potent
inhibitor of HPV infection. While XXI prevents the escape of the
viral DNA from the endosome, the proteolytic target for γ-
secretase and how it relates to HPV infection remains unknown.
Given that furin cleavage is a necessary intermediate step in
infection, the inhibition of HPV16 fcPsV infection by XXI both
in vitro and in vivo (Fig. 4E and F) demonstrates that γ-secretase
acts after furin during HPV infection.
Natural PV infection frequently triggers an antibody response
to L1, but rarely to L2. Likewise, vaccination with virions or L1/L2
VLP induces a potent L1-speciﬁc response, whereas minimal titers
are observed to L2, whereas vaccination with L2 alone does induce
a strong L2-speciﬁc antibody response. The subdominance of L2 in
the context of the capsid may reﬂect its low stoichiometry L1
(r1:5) and wider spacing compared to L1, and that L2 is
predominantly buried below the capsid surface (Roden et al.,
2000). Indeed, L2 epitope display by insertion into an immuno-
dominant epitope of the major capsid antigen for HPV and non-
HPV VLPs does enhance its immunogenicity (Schellenbacher et al.,
2009; Tumban et al., 2011). In contrast, fcPsV particles display the
L2 17-36 epitope with an untethered end in the ordered array of
the capsid surface (Buck et al., 2008). Nevertheless, no signiﬁcant
L2 antibody titer was detected after vaccination with fcPsV despite
a robust L1-speciﬁc response (Fig. 5B). The continued dominance
of L1 responses for fcPsV may reﬂect both the Z5:1 ratio of L1 to
L2 in the capsid, and greater spacing between the L2 versus L1
epitopes. Further, since the amino terminus of L2 contains cross-
type protective epitopes, we speculate that the sub-dominance of
this region conveys evolutionary advantage by preventing a singly
infected host from developing broad immunity to other PV
infections.
L2 has received attention as a target antigen for second
generation HPV vaccine development because of its potential to
induce broad immunity. Clinical development of HPV vaccines
requires an effective immune correlate. Given the central role of
neutralizing antibodies in protection, it is critical to have an in vitro
neutralization assay to measure the relevant immune correlate.
While the classical PsV-based neutralization assay (293TT assay)
has proven a useful correlate for L1 VLP vaccines, it is insensitive
for detection of L2-speciﬁc neutralizing antibody and also cross-
protective L1 responses in weaker sera. Recently an L2-speciﬁc
neutralization assay has been described (Day et al., 2012b). This
involves creating a basement membrane-like environment that
generates furin-cleaved virions before the neutralization assay is
carried out. Brieﬂy, an ECM derived from a breast cancer cell line is
ﬁrst laid down before adding virions. Virion interaction with this
environment triggers conformational change leading to exposure
of L2. Supernatant from a separate furin secreting cell line is
subsequently added to exert furin cleavage. Lastly, a heparin-
deﬁcient CHO cell line, PGSA-745 is added to the mixture as the
targeted host cell and expression of the reporter GFP is detected by
ﬂow cytometry. While the assay has proven to be superior to the
classical 293TT/L1-assay, several recognized limitations exist.
Firstly, several cell lines need to be maintained and from a quality
control perspective, it is also technically challenging to ensure
consistently that equivalent amounts of furin from a cell super-
natant is added each time. Secondly, PGSA-745 cells are of non-
human origin and while the lack of HSPG in PGSA-745 will limit
the infectivity to only furin cleaved virions, the absence of
T-antigen in these cell lines suggests similar problems in reporter
signal activity would be experienced with “weaker” HPV PsV.
To circumvent such issues and based upon the concepts
illustrated by Day et al. (2012b), we have developed an alternative
high through-put neutralization assay via the use of fcPsV.
Importantly, the fcPsV approach uses a format analogous to the
classical 293TT assay. It is based upon the neutralization of fcPsV
infection of a furin-deﬁcient human cell line stably expressing the
SV40 T-antigen (LoVoT). This fcPsV assay exhibits signiﬁcantly
improved sensitivity in measuring neutralization by L2-speciﬁc
antisera and monoclonal antibodies by 10–300 fold, and yet
maintains similar sensitivity for type-restricted responses to L1
VLP (Table 2).
Vaccination with Cervarix confers protection against HPV 31
and 45 infection in both people and mice (Malagon et al., 2012;
Wheeler et al., 2012). However, using the 293TT assay, no cross-
neutralization titers for HPV45 were detected in the sera of mice
vaccinated with Cervarix although cross-neutralization titers were
detected for HPV31. The use of the LoVoT assay however revealed
similar levels of neutralizing titers against HPV31 in sera from
mice vaccinated with Cervarix and even detected the presence of
low titer neutralizing antibodies to HPV45 (Table 2). This ability to
better detect low titer cross-neutralizing L1 antibody titers sug-
gests that the conformation of fcPsV may better display these
cross-protective L1 epitopes than mature PsV. Taken together,
these results indicate that the LoVoT assay not only detects L2-
speciﬁc antibodies with enhanced sensitivity, but potentially also
cross-neutralizing L1-speciﬁc antibodies, without compromising
the measurement of type-speciﬁc antibodies to L1 VLP (Table 2).
In summary, our results support the utility of fcPsV system to
study several biological and immunological properties of HPV
while in its furin-cleaved intermediate conformation. In addition,
the LoVoT-based neutralization assay has promise as a tool in HPV
vaccine development, especially for evaluating L2-speciﬁc and L1-
cross neutralization.
Materials and methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All animal studies
were performed with the prior approval of the Animal Care and
Use Committee of Johns Hopkins University (protocol MO08M19).
Human tissue samples were collected following informed consent
of the patient or the patient's guardian in accordance to the Ethics
Committee of the Medical University Vienna (ECS 1327/2012).
Plasmids
The plasmid vectors pShell expressing codon optimized L1 and
L2 capsid genes of HPV16, 45 and 58 were kind gifts from John
Schiller, NCI. Additional PsV genotypes HPV6, 11, 18, 31 and 33
codon optimized L1 and L2 capsid genes were sub-cloned into
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double expression vector pVITRO1-neo-mcs (Invivogen, San Diego
CA). The human furin cDNA (NM_002569.2) was obtained from
Sino Biological Inc and was sub-cloned into pIRESpuro2 (Clontech
Laboratories Inc, USA) between the AﬂII and BstB1 restriction sites
after PCR ampliﬁcation using primers 5′-GAGAGACTTAAGATG-
GAGCTGAGGCCCTGG (forward) and 5′-GACCGATTCGAATCATCA-
GAGGGCGCTCTGGTC (reverse) to yield Furin-pIRESpuro2. Mouse
papillomavirus (MmuPV1) plasmids pMusPV, pMuL2w, pMus-
SheLL and the SV40 T-antigen plasmid, pTIH were kind gifts from
Christopher Buck, NCI. MmuPV1-L2 was sub-cloned into pet28a
(þ) vector (Novagen, San Diego, CA) between the BamH1 and
Xho1 restriction sites after PCR ampliﬁcation of codon optimized
MmuPV1-L2 gene from pMuL2w using primers 5′-GAGAGAG-
GATCCATGGTCAGCGCCGATCGCTCA (Forward) and 5′-GACCGACTC-
GAGGTA GATCCTGTACTTCCGCTTGCGCTT to yield MmuPV1-L2-
pet28a(þ).
Cell culture and creation of cell lines 293TTF and LoVoT
All cell lines were maintained in DMEM supplemented with
10% FBS, 1 penicillin and streptomycin, 1 non-essential amino
acids and 1 Sodium Pyruvate (Gibco Life technologies, Grand
Island NY). For the creation of 293TTF and LoVoT, 5106 293TT or
LoVo cells/well respectively were seeded into a six well plate the
day before transfection. Individual wells were transfected with
either no template (mock transfection) or either Furin-pIRESpuro2
into the 293TT cells or pTIH into the LoVo cells respectively using
Mirus TransIT 2020 (Mirus Bio, Madison WI) according to manu-
facturer's protocol. After 48 h, the cells were harvested using 0.5%
trypsin and each well re-seeded into individual 10 cm2 plates. Both
control and transfected cells were treated with complete growth
media with either puromycin concentration of 2 μg/mL for 293TT
cells, or with 200 μg/mL Hygromycin B for LoVo cells. Fresh media
was introduced every 4 days until all the control cells died and the
appearance of clonal colonies in the transfected plate. Colonies
were picked using cloning cylinders (Milipore) as per manufac-
turer's recommendations and expanded. The furin-deﬁcient cell
line FD11 (Gordon et al., 1995) and the FD11-F cell line in which
furin expression is complemented by ectopic expression of the
furin gene in FD11 cells, were both gifts from Tae Heung Kang and
TC Wu (Johns Hopkins University, Bethesda, MD). The LoVo cell
line (Drewinko et al., 1976) was a kind gift from Weijie Poh and
James Herman Lab (Johns Hopkins University, Bethesda, MD).
PGSA-745 cells (Esko et al., 1985) were a kind gift from John
Schiller (National Cancer Institute, Bethesda, MD).
Pseudovirion (PsV) and furin-cleaved pseudovirion (fcPsV) production
Standard PsV were generated in 293TT cells following the
previously described production protocol (http://home.ccr.cancer.
gov/Lco/pseudovirusproduction.htm). Fireﬂy luciferase expression
plasmid was employed as the reporter for PsV infection in both
neutralization assays and for mice vaginal challenge studies. Furin-
cleaved PsV (fcPsV) were generated by following the same stan-
dard PsV production protocol but with the following modiﬁca-
tions: (1) 293TTF cells were used instead of 293TT cells;
(2) maturation buffer did not contain ammonium sulfate; (3) CaCl2
was added to the maturation buffer to 5 mM; and (4) maturation
was carried out for 48 h instead of 24 h. The protocol was also
suitable for producing fcPsV encapsidating GFP or SEAP reporter
and the former was used in time-course assays. Transmission
electron microscopy (TEM) analysis on the puriﬁed virions were
performed as described in Buck et al. (2008)
Generation of infectious mouse papilloma virions (MmuPV1) and
mouse papilloma tail lesions
The synthetic MmuPV1 genome plasmid (pMusPV) was excised
from its vector backbone and re-ligated by adapting an earlier pro-
tocol (http://home.ccr.cancer.gov/lco/religation.htm). Co-transfection
of pMusSheLL containing the codon optimized sequences of MmuPV1
L1, L2 and the re-ligated MmuPV1 genome into 293TT cells and the
following remaining steps of the standard PsV protocol produce
infectious MmuPV1 virions. Five athymic nude mice (NCr-nu/nu) were
subsequently challenged on their tails with 200 mL of the puriﬁed
MmuPV1 virion as described in Cladel et al. (2013). Papilloma-like
lesions were observed on the tails subsequently after 5 weeks. These
mice were then euthanized and mouse papillomas were collected,
snap frozen in liquid nitrogen and stored at 80 1C until further use.
Western blot analysis and quantiﬁcation
Primary antibodies used for L2 detection were mouse mono-
clonal antibody RG1 (Gambhira et al., 2007) to HPV16 L2 17-36, or
rat monoclonal antibody WW1 that recognizes the same epitope
and also neutralizes HPV16 (Wu et al., 2012). Primary antibody for
furin and T-antigen detection was respectively B-6 and PAB101
(sc-133142 and sc-147, Santa Cruz Biotechnology, Dallas, TX).
Respective secondary antibodies include HRP-goat anti-mouse
IgG light chain or HRP-donkey anti-rat IgG HeavyþLight chain
(Jackson ImmunoResearch, West Grove PA). For 293TT and 293TTF
supernatant analysis, cells were seeded in DMEM (10% FBS, 1
penicillin/streptomycin) at 500,000 cells/well in a six well plate in
the presence or absence of puromycin (2 μg/mL). After 48 h, the
wells were washed three times with PBS and serum free media
(plus puromycin 2 μg/ml for 293TTF) was added for 24 h. Subse-
quently, media was collected and spun at 1600 rpm for 4.5 min at
room temperature to remove any debris. The supernatant was
concentrated using 50 kDa Centricon concentrators (Milipore,
Billerica, MA) and subsequently used for western blot analysis.
Intensity of bands was analyzed using the NCI software ImageJ
(http://rsb.info.nih.gov/ij/index.html). For comparison of L2 bands
in the various clinical warts samples, virions were extracted from
the samples using the following protocol (http://home.ccr.cancer.
gov/lco/VirionExtraction.htm). HPV26, HPV57 L2 was detected
using WW1, HPV6 L2 was detected using L2α(11–88)x8 rabbit
serum made as described in (Jagu et al., 2013b), BPV-1 L2 was
detected with mouse monoclonal antibody C6, and MmuPV1 L2
was detected with mouse anti-MmuPV1-L2 sera.
L1/L2 VLP vaccination and generation of MmuPV1-L2 anti-sera
Groups (n¼10) of 8–10 week old female Balb/c mice were
vaccinated s.c. three times at 2 week intervals with L1/L2 VLP
(5 mg), or furin-cleaved L1/L2 VLP (5 mg) formulated with alum
(50 mg) and MPL (5 mg), or 50 mL of Cervarix™, or PBS alone, or PBS
with adjuvants alum (50 mg) and MPL (5 mg). Blood samples were
collected 2 weeks after the second and third vaccination. For
MmuPV1-L2 immunization, MmuPV1-L2 protein was synthesized
by bacterial induction using the MmuPV1-L2-pet28a(þ). Follow-
ing protein induction and puriﬁcation and dialysis (See (Jagu et al.,
2013a) for full method details), ﬁve 8–10 week old female Balb/c
mice were vaccinated s.c. with 25 μg of puriﬁed MmuPV1-L2
protein formulated with alum (50 μg) and MPL (5 μg) three times
at 2 week intervals. Blood was collected a week after the ﬁrst
boost. In both immunization regimens, following blood collection,
the blood samples were clotted o/n at 4 1C and serum was
collected after centrifugation at 2000 g for 10 min at 4 1C.
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ELISA
For analysis of antibody response against HPV16 L1-VLP and L2
full length protein, maxisorp microtiter 96-well plates (Thermo
Scientiﬁc Nunc, Waltham MA) were coated with either L1-VLP or
L2 protein at 500 ng in 100 mL PBS/well and incubated overnight at
4 1C. The next day, plates were blocked with PBS/1% BSA for 1 h at
37 1C. Serum samples diluted 1:50 in PBS/1% BSA were then added
to the plates for 1 h at 37 1C. Following this, plates underwent
3 washes with washing buffer (0.01% Tween 20 in PBS) before
HRP-sheep anti-mouse IgG diluted 1:5000 in 1% BSA was added to
each well and plates were incubated for 1 h at 37 1C. After three
further washes, 100 mL of ABTS solution, 2,2′Azinobis [3-ethylben-
zothiazoline-6-sulfonic acid] (Roche, Basel Switzerland) was added
to each well for development, and absorbance at 405 nm read
using a Benchmark Plus (Bio Rad, Hercules CA).
In vitro neutralization assays
Serum samples (4 mL) were serially diluted two-fold in culture
media, and mixed with HPV PsV or fcPsV (0.1 mg/mL of L1) carrying
luciferase reporter plasmid. Mixtures were incubated at 37 1C for
2 h, added to 293TT, FD11 or LoVoT cells that had been plated at
15,000 cells/well 1 day prior. Approximately, 5-fold more fcPsV
was required for assays using LoVoT and 50-fold for FD11cells as
compared to 293TT cells e.g. at a 1:5000 or 1:1000 dilution of virus
for 293TT and LoVoT respectively. These plates were incubated at
37 1C. After 72 h, cells were lysed with 30 mL of Cell Culture Lysis
Reagent (Promega, Madison WI) for 15 min at room temperature
on a rocking platform. The entire lysates were transferred to a 96-
well black plate, and luciferase activity was measured by adding
50 ml of luciferin substrate to each well (GloMaxs-Multi Detection
System, Promega, Madison WI). The same procedure was carried
out for FD11 or LoVoT based neutralization assays.
Pull down assays
Immuno-precipitation studies were performed using Dyna-
beadss Protein G (Life Technologies, Grand Island NY) according
to manufacturer's protocol with some adjustments. Brieﬂy, 10 mg
of RG-1 monoclonal antibody was mixed with 1.5 mg of Dyna-
beads protein G and incubated on a rotator for 30 min at room
temperature. Subsequently, equal amounts of puriﬁed fcPsV and
PsV based on L1 content were added and the mixture was
incubated on a rotator overnight at 4 1C. Washing and elution of
bound virions were performed as per manufacturer's protocol.
Elutes were subjected to western blot analysis.
Assay of neutralization and inhibition of infection
293TT, LoVoT or PGSA-745 cells were seeded at 15,000 cells/
well in 100 mL of medium in a 96-well plate and incubated
overnight. The next day, for neutralization assays, using another
96-well plate, the serum to be tested was serially 2-fold titrated
across the plate in a total volume of 50 mL. Following this, 50 mL of
equivalent amounts of PsV and fcPsV based on L1 amount was
added to make the antibody–virus mixture 100 mL. The plates were
incubated at 37 1C for 2 h before the mixture was added onto the
pre-plated cells and incubated for 72 h. The total volume of 200 mL
resulted in the starting dilution for most L2 serum was at 1:50
while L1-serum was at 1:200. For inhibitor assays, using another
96-well plate, the relevant inhibitors in either sterile water or
DMSO were subjected to a 2-fold serial dilution with the highest
dilution starting at 256 mg/ml. Titrated PsV in 50 mL was then
added to the diluted candidate inhibitor and this mixture (100 mL)
was immediately added to the pre-plated cells. Regardless of assay
type, the plates were incubated for 72 h and cells were lysed with
30 mL of Cell Culture Lysis Reagent (Promega, Madison WI) for
15 min at room temperature on a rocking platform. The entire
lysates were transferred to a 96-well black plate, and luciferase
activity was measured by GloMaxs-Multi Detection System (Pro-
mega, Madison WI) after adding 50 mL of luciferin substrate
(Promega, Madison WI) to each well. IC50 values or titers were
calculated using Prism (GraphPad Software, San Diego CA).
Approximately, 5-fold more fcPsV was required for assays using
LoVoT and PGSA-745 cells as compared to 293TT cells.
For the time course infectivity assay, 293TT cells were pre-
plated at 60,000 cells/well in a 24 well plate and incubated at 37 1C
overnight. The next day, equal amounts of HPV16 PsV or fcPsV16
(based on L1 amount) encapsidating a GFP reporter plasmid was
added to the cells. Following this, at time points 24, 48 and 72 h
after addition of virus to the cells, the cells were harvested with
trypsin-EDTA (1 ) (Gibco, Life technologies, Grand Island NY),
and washed with 1 mL of ﬂuorescence-activated cell sorter (FACS)
buffer (0.5% BSA in PBS, pH 7.4). The cell pellet was then
resuspended in 300 mL of 1 FACS buffer and GFP expression as
an indicator of infectivity was analyzed by ﬂow cytometry with a
Becton Dickinson FACSCalibur. The experiment was performed in
triplicate and % infectivity data was analyzed using CellQuest
software (Becton Dickinson Immunocytometry).
Mouse vaginal challenge studies
Four days before vaginal challenge, 8–10 weeks old Balb/c mice
purchased from NCI were subcutaneously injected with 3 mg of
medroxyprogesterone (Depo-Provera, Pﬁzer, New York NY). PsV or
fcPsV stock amounts were standardized based on their L1 content.
Each mouse was challenged with 2 mg of PsV or fcPsV (based on
stock virus with L1 content of 0.2 mg/mL) which was pre-mixed for
an hour with the relevant inhibitors or an equal volume of diluents
with 3% (w/v) carboxymethyl cellulose (CMC) except for the 1%
(w/v) carageenen for which CMC was omitted. The amount of
Heparin used (based on previous data) was 1000-fold in excess to
the L1 content (Johnson et al., 2009). Approximately, 200 mM of
Gamma secretase inhibitor XXI was used, premixed for 1 h with
either PsV or fcPsV that were instilled into the vaginal vault before
and after cytobrush treatment (15–20 rotations, alternating direc-
tions), while the mice were under isoﬂurane anesthesia. Forty-
Table 1
Summary of neutralization assay titers against HPV16 comparing the conventional HPV16 PsV neutralization assay and using fcPsV in FD11 cells. Mean neutralization titers
based on the reciprocal of the dilution that causes 50% reduction in luciferase activity is recorded. P-value is based on Wilcoxon matched-pairs signed rank test.
Serum/monoclonal antibody used (replicates) 293TT assay neutralization
titers (mean)
FD11 assay neutralization
titers (mean)
Approximate
fold change
P-
value
L2α (11–88)x5 (n¼8) 788 8150 10 0.0078
L2α (11–88)x8 (n¼10) 1270 9480 11 0.0156
Mouse monoclonal antibody, RG-1 (n¼10) 320 88,320 276 0.0020
Rat monoclonal antibody, WW1 (n¼10) 70 76,800 1097 0.0020
Cervarix™ (n¼10) 228,280 143,360 1.5 0.1055
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eight hours after challenge, mice were anesthetized by isoﬂurane,
and 20 mL of luciferin substrate (7.8 mg/ml, Promega, Madison WI)
was delivered into the vaginal vault before imaging. Biolumines-
cence was acquired for 10 min with a Xenogen IVIS 100 (Caliper
Life Sciences, Hopkinton MA) imager, and analysis was accom-
plished with Living Image 2.0 software. For γ-secretase inhibitor
studies, imaging was performed 72 h post-challenge.
Statistical analysis of neutralization assay titers
For comparison of the 293TT and FD11-based assays, titers
were determined using both assays for individual mouse sera
(Table 1) using samples obtained from animals vaccinated in a
prior study (Jagu et al., 2013b). Neutralization titers (the reciprocal
of the dilution that causes 50% reduction in luciferase activity)
were recorded for each individual serum and the sample average
was calculated within each group. Nonparametric Wilcoxon
signed-rank test was performed to detect statistical signiﬁcance
between the two groups. For comparison of 293TT assay against
LoVoT assay (Table 2), the same mouse serum samples from (Jagu
et al., 2013b) were pooled and underwent inter-assay triplicate
comparison. Neutralization titers (EC50) reported are the mean of
this triplicate testing. The non-linear model Y¼Bottomþ(Top–
Bottom)/(1þ10((LogEC50-X)nHillSlope)) was ﬁtted to log-transformed
neutralization titers data. The estimated EC50s and their 95%
conﬁdence intervals are reported. Statistical calculations were
performed using GraphPad Prism version 6.
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